The Effects of Progestins

October 2011
Fertility Weekly;10/17/2011, p1
Academic Journal
The article presents a study conducted by H. Okada and colleagues in Japan which investigates the inhibitory effects of progestins on human endometrial stromal cells (ESCs) in vitro. The study discovers that vascular endothelial growth factor (VEGF) and stromal cell-derived factor 1 (SDF-1), which are both present in ESCs, are inhibited by progestins. Researchers believe that data in their study suggest a mechanism for the action of steriods in angiogenesis of human endometrium.


Related Articles

  • Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1. GUO-CAI LI; HONG-WEI ZHANG; QING-CHUN ZHAO; LI SUN; JIAN-JUN YANG; LIU HONG; FAN FENG; LEI CAI // Oncology Letters;Feb2016, Vol. 11 Issue 2, p1089 

    Mesenchymal stem cells (MSCs) may influence the growth and metastasis of various human malignancies, including hepatocellular carcinoma (HCC). Therefore, the underlying mechanisms via which MSCs are able to affect malignancies require investigation. In the present study, the potential role of...

  • VEGFR2-dependent Angiogenic Capacity of Pericyte-like Dental Pulp Stem Cells. Janebodin, K.; Zeng, Y.; Buranaphatthana, W.; Ieronimakis, N.; Reyes, M. // Journal of Dental Research;Jun2013, Vol. 92 Issue 6, p524 

    Dental pulp stem cells (DPSCs) have previously demonstrated potential pericyte-like topography and function. However, the mechanisms regulating their pericyte function are still unknown. In this study, murine DPSC angiogenic and pericyte function were investigated. Tie2-GFP mouse DPSCs were...

  • Investigation of Antiangiogenic Tumor Therapy Potential of Microencapsulated HEK293 VEGF165b Producing Cells. Afkhami, Fatemeh; Durocher, Yves; Prakash, Satya // Journal of Biomedicine & Biotechnology;2010, p1 

    To investigate the antiangiogenic potential of encapsulated VEGF165b producing HEK293 cells, Human Embryonic Kidney 293 (HEK293) cells were stably transfected to produce VEGF165b. Then they were encapsulated in alginate - polylysine -alginate (APA) microcapsules. VEGF165b productivity and...

  • An endothelium-derived angiogenesis inhibitor vasohibin and its significance in tumor angiogenesis. Sato, Yasufumi // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p69 

    Angiogenesis is regulated by a local balance between the levels of endogenous stimulators and inhibitors of angiogenesis. Understanding of the mechanism of angiogenesis has advanced significantly since the discovery of two members of the family of angiogenesis stimulators—vascular...

  • Hypoxic stress simultaneously stimulates vascular endothelial growth factor via hypoxia-inducible factor-1α and inhibits stromal cell-derived factor-1 in human endometrial stromal cells. Tsuzuki, Tomoko; Okada, Hidetaka; Cho, Hisayuu; Tsuji, Shoko; Nishigaki, Akemi; Yasuda, Katsuhiko; Kanzaki, Hideharu // Human Reproduction;Feb2012, Vol. 27 Issue 2, p523 

    BACKGROUND Hypoxia of the human endometrium is a physiologic event occurring during the perimenstrual period and the local stimulus for angiogenesis. The aim of this study was to investigate the effects of hypoxic stress on the regulation of vascular endothelial growth factor (VEGF) and stromal...

  • Management of hypertension in angiogenesis inhibitor-treated patients. Izzedine, H.; Ederhy, S.; Goldwasser, F.; Soria, J. C.; Milano, G.; Cohen, A.; Khayat, D.; Spano, J. P. // Annals of Oncology;May2009, Vol. 20 Issue 5, p807 

    Background: Hypertension (HTN) is one of the most frequent side-effects of systemic inhibition of vascular endothelial growth factor (VEGF) signaling. Its incidence and severity are dependent on the type of drugs, dose, and schedule used. The recognition of this side-effect is an important issue...

  • Angiogenesis: Inside or outside? Seton-Rogers, Sarah // Nature Reviews Cancer;Oct2007, Vol. 7 Issue 10, p728 

    The article focuses on the inhibition of tumor angiogenesis using therapies directed against vascular endothelial growth factor (VEGF) for vascular homeostasis. It has shown clinical efficacy against various tumor types. However, these inhibitors can induce toxicities through disrupting normal...

  • Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Fujisaka, Yasuhito; Yamada, Yasuhide; Yamamoto, Noboru; Shimizu, Toshio; Fujiwara, Yutaka; Yamada, Kazuhiko; Tamura, Tomohide; Watanabe, Hiroyuki; Yu-Nien Sun; Bass, Michael B.; Seki, Mitsuo // Cancer Chemotherapy & Pharmacology;Oct2010, Vol. 66 Issue 5, p935 

    The aim of this study was to investigate the safety and pharmacokinetics of motesanib (AMG 706), a small-molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and c-Kit in Japanese patients with advanced solid tumors. Patients...

  • Phase III setback for lead angiopoietin inhibitor. Mullard, Asher // Nature Reviews Drug Discovery;Dec2014, Vol. 13 Issue 12, p877 

    The article discusses the effectiveness of the anti-angiogenesis drugs such as Genentech/Roche's blockbuster bevacizumab that inhibits vascular endothelial growth factor (VEGF) wherein it offers efficacy in oncology indications associated with limited side effects.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics